Valuation : Vaxart, Inc.

Market Cap 123M 105M 98.69M 90.14M 170M 11.68B 171M 1.17B 453M 5.89B 460M 450M 19.52B P/E 2026 *
-3.15x
P/E 2027 * -0.59x
Enterprise Value 123M 105M 98.69M 90.14M 170M 11.68B 171M 1.17B 453M 5.89B 460M 450M 19.52B EV / Sales 2026 *
1.03x
EV / Sales 2027 * 52.1x
Free-Float
98.56%
Yield 2026 *
-
Yield 2027 * -
1 day+0.40%
1 week+1.35%
Current month-6.57%
1 month+1.92%
3 months-20.24%
6 months-32.82%
Current year+45.64%
1 week 0.49
Extreme 0.4901
0.56
1 month 0.45
Extreme 0.4511
0.64
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
9.4
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%+1.35%+41.47%-35.92% 123M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.23%+2.62%+49.51%+93.44% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-0.49%+1.73%+59.01%+11.60% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
+1.20%+2.01%+37.62%-16.96% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%-1.59%+13.19%+543.56% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average +0.54%+1.18%+57.91%+174.01% 28.84B
Weighted average by Cap. +1.09%+0.72%+56.58%+157.59%

Financials

2026 *2027 *
Net sales 119M 102M 95.54M 87.26M 165M 11.31B 165M 1.13B 438M 5.71B 445M 436M 18.9B 2.35M 2.02M 1.89M 1.73M 3.26M 224M 3.28M 22.4M 8.68M 113M 8.82M 8.63M 375M
Net income -47.2M -40.51M -38.02M -34.73M -65.54M -4.5B -65.86M -450M -174M -2.27B -177M -173M -7.52B -222M -190M -179M -163M -308M -21.13B -309M -2.11B -819M -10.66B -832M -814M -35.31B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change
26/08/26 $0.5045 +0.40%
25/08/26 $0.5025 +0.40%
24/08/26 $0.5005 -2.82%
21/08/26 $0.5150 -0.90%
20/08/26 $0.5197 +4.41%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5045USD
Average target price
3.333USD
Spread / Average Target
+560.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock